Other Relevant News
PsyTech Hosts Live Investor Conference & Webinar October 27, 2020 and Closes Transaction with One of the Largest Psychedelic Conferences PsyTech.biz
Globe News Wire, 25 September, 2020
PsyTech Summit 2020 will be a one-day, international event bringing together decision makers, investors, clinicians, thought leaders, and advocates for the purpose of advancing psychedelics science, business, and reform. Mind Medicine Australia Executive Director, Tania de Jong AM will be presenting alongside other distinguished speakers associated with Mind Medicine Australia including Professor David Nutt, Dr Rick Doblin, Professor Matthew W. Johnson, Dr Robin Carhart-Harris, Dr Adele Lafrance and Dr Reid Robison.
Washington Post, September 21, 2020
Who Will Benefit From Psychedelic Medicine? These substances are being touted as a game-changing intervention for mental health. But it’s not clear if their promise will be accessible to all.
Bezinga, September 19, 2020
On Friday, UK-based mental health care company Compass Pathways NASDAQCMPS announced it has begun trading on NASDAQ under the symbol CMPS. This is the first time a psychedelics company is listed on a major U.S. Stock Exchange.
Fierce Pharma, September 16, 2020
Drug delivery specialist IntelGenx has penned two deals to develop film-based, prescription psychedelics amid a surge of interest—and investment—from the biopharma industry.
Berkeleyside, September 18, 2020
UC Berkeley launches center for psychedelic science and education With $1.25M in seed funding, the new center will conduct research using psychedelics to investigate cognition, perception and emotion and their biological bases in the human brain.
Ben Comer, Pharma Intelligence, September 9, 2018
Investigational uses of psilocybin and MDMA – two illicit drugs associated with recreational use and abuse in the US – will soon enter the later stages of clinical development for the treatment of CNS disorders including depression, addiction and post-traumatic stress disorder.
Download the article here as PDF.
Cannabis Life Network, August 22, 2020
There are a lot of negative stigma surrounding psychedelic drugs. A large portion of the population and the government condemn these substances to be dangerous, addictive, and illegal. Although, that may be true when it comes to opiates or stimulants (such as heroin or cocaine). As they are, indeed, physiologically toxic and addictive. Psychedelics, on the other hand, have been mistaken to have the same, or even worse detrimental effects to one’s health.
The Wall Street Journal, August 20, 2020
A group of Silicon Valley and Wall Street executives has raised $30 million to speed the development of a closely watched psychedelic-drug therapy using the key ingredient of the party drug Ecstasy to treat trauma patients.
DocWire News, August 19, 2020
The medium to long term consequences of COVID-19 are not yet known, though an increase in mental health problems are predicted. Multidisciplinary strategies across socio-economic and psychological levels may be needed to mitigate the mental health burden of COVID-19.
Fierce Biotech, August 13, 2020
Psychedelic drugs like LSD have long been of interest in the medical community because of their anti-inflammatory properties. But efforts to transform them into therapeutics have been hampered by laws restricting the use of psychedelics, not to mention the stigma associated with them.
Regina Leader-Post, Aug 21, 2020
Earlier this month, four Canadians received Section 56 exemption to the Controlled Drugs and Substances Act, allowing them to pursue psilocybin therapy for end-of-life distress.
CNN, August 6, 2020
Four cancer patients in end-of-life care will be become the first people in decades to legally possess and consume psilocybin mushrooms in Canada after a landmark decision.
60 Minutes USA, July 21, 2020
Anderson Cooper sits down with Jon Kostakopoulos to discuss his experience as a clinical participant in an NYU psilocybin study treating alcohol use disorder.
New Atlas, July 23, 2020
A new review from neuroethicist Eddie Jacobs, and published in the Journal of Psychedelic Studies, is suggesting psilocybin may have great potential as a treatment for obsessive-compulsive disorder (OCD).
The Guardian, July 4, 2020
As more troops self-medicate with psychedelic drugs to help with PTSD, a group of experts lobby for proper clinical trials.
Dr Robin Carhart-Harris, The Guardian, June 8, 2020
Imperial College, UK have been comparing psilocybin to conventional antidepressants – and the results are likely to be game-changing
Dr Robin Carhart-Harris is a member of the Mind Medicine Australia advisory panel.
Dr Tony Bartone, Professor Ian Hickie AM, Professor Patrick McGorry AO, AMA Joint Statement, June 2, 2020
Australia will likely see increases in youth suicide and a surge in demand for specialist mental health services as the full and lasting impact of the COVID-19 pandemic is experienced across the community.
David H., The Cannabis Investor, May 27, 2020
Organizations forming today will build the infrastructure which, three to five years from now, will be delivering psychedelic medicines to the world.
Interim Analysis Shows At Least 90% Chance of Statistically Significant Difference in PTSD Symptoms after MDMA-assisted Psychotherapy
Brad Burge, Multidisciplinary Association for Psychedelic Studies (MAPS), May 13, 2020
Results are the strongest confirmation that an interim analysis can provide
Beckley Foundation, November 17, 2017
Watch our brains become more connected on psilocybin, and learn how psychedelics can help treat conditions such as depression, addiction, and PTSD.
Dr Norman Swan, On Breakfast Program with Hamish Macdonald, ABC Radio National, November 11, 2019
Research into psychedelic drugs like LSD is growing, encouraged by positive early trials. Scientists think these drugs could treat things like post-traumatic stress disorder and depression.
Sam Levin, The Guardian, June 5, 2019
Yesterday Oakland became the second city in the US to decriminalize magic mushrooms and other psychedelics.
Johns Hopkins and NYU studies in psilocybin as a treatment for cancer-related psychological distress.
News outlets included CNN, New York Times, Newsweek, PBS Newshour, Science, Scientific American, The Atlantic, The Guardian, Time, and USA Today, among others.
Two clinical studies (released Dec. 1, 2016) examining the effect of psilocybin on symptoms of depression and anxiety in people with life-threatening cancer were released and covered by a number of media.
Vox June 27, 2016
Show Me the Evidence staff examines more than 50 studies analyzing the safety and efficacy of psychedelic drugs and psychedelic-assisted therapy and interviews researchers involved in the work. Vox, 2016
Zoe Cormier, Nature, May 17, 2016
Imperial College study provides preliminary support for the safety and efficacy of psilocybin as a therapy for treatment-resistant depression. Nature, 2016
Douglas Main, Newsweek, April 19, 2016
Researchers at the University of Zurich show that a small amount of psilocybin can reduce the distress caused by mild social exclusion and lessens activity in the area of the brain associated with this emotion. Newsweek, 2016
The Lancet Psychiatry, April 5, 2016
Drug-assisted psychotherapy as a possible alternative to existing pharmacological and psychological treatments. (Free registration required)
Washingtonian, January 7, 2014
Recent John’s Hopkins study on effecting addictive behaviour with psychedelics. Washingtonian, 2014